National Cancer Institute (nci)

This study is testing a stem cell transplant as a potential cure for DOCK8 deficiency, a rare genetic disorder that severely weakens the immune system. The trial is enrolling patients aged 4-35 who have suffered life-threatening infections and have a matched donor. Researchers ar…

This study is testing if a different timing schedule for the HPV vaccine works well in healthy 9-11 year old children. The HPV vaccine can prevent several types of cancer caused by the virus. Researchers want to see if giving the first shot and then waiting two years for the boos…

This study is comparing two hormone therapy drugs, tamoxifen and a newer drug called Z-Endoxifen, for postmenopausal women whose breast cancer has spread and is fueled by estrogen. The goal is to see if Z-Endoxifen can keep the cancer from growing for a longer period than the sta…

This study is testing whether combining two immunotherapy drugs with a precise form of radiation can better control aggressive brain tumors that have returned after previous radiation. It aims to find the safest dose and see if this approach shrinks tumors in adults with recurren…

This early-stage study aims to find the safest and most effective doses of two oral drugs, lenalidomide and ibrutinib, when given alongside the standard antibody drug rituximab. It involves 33 adults with previously untreated stage II-IV follicular lymphoma, a type of slow-growin…

This large, late-stage trial is testing whether adding the immunotherapy drug nivolumab after standard chemoradiation treatment can help prevent cancer from returning in patients with high-risk anal cancer. The study involves 344 adults who have completed initial treatment. Parti…

This early-stage study is testing the safety and best dose of a new drug called uproleselan when given with two standard chemotherapy drugs (fludarabine and cytarabine). It is for children and teenagers (ages 1-17) whose acute myeloid leukemia, myelodysplastic syndrome, or mixed …

This study is testing a new combination of three oral drugs for adults with advanced melanoma that has a specific BRAF gene mutation and has stopped responding to standard targeted therapy. The goal is to find a safe dose and see if adding a new drug (tazemetostat) to two existin…

This large, late-stage trial is testing whether adding an immunotherapy drug (atezolizumab) to the standard treatment of chemotherapy and radiation helps people with limited-stage small cell lung cancer live longer. About 544 participants are randomly assigned to receive either t…

This large, late-stage trial is testing if adding a new oral drug (AZD6738) to an existing immunotherapy (durvalumab) works better than the immunotherapy alone to keep non-small cell lung cancer from coming back. It is for patients who have already had chemotherapy and surgery to…

This study is testing whether adding a new drug called veliparib to standard radiation and chemotherapy can better control aggressive brain tumors in children and young adults. The treatment aims to stop cancer cells from repairing themselves, making them more vulnerable. The stu…

This study is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to standard platinum-based chemotherapy. It aims to see if taking two oral drugs, cediranib and olaparib, together works better than taking either drug alone or…

This study is testing whether a drug called cabozantinib, alone or combined with an immunotherapy drug (nivolumab), works better than standard chemotherapy for people with a specific type of advanced lung cancer that has worsened after initial treatment. It involves about 117 par…

This study is testing whether the drug copanlisib can help treat advanced cancers that have lost a specific protein called PTEN. The drug aims to block signals that cancer cells need to grow. The trial includes about 22 patients with various solid tumors that have not responded t…

This study is testing several drug combinations to see if they work better than single drugs at controlling advanced endometrial cancer that has returned or spread. It involves 288 women whose cancer has come back after prior treatment. Researchers are comparing different pairs o…

This study is testing whether the immunotherapy drug nivolumab can help prevent lung cancer from returning after surgery and chemotherapy. It involves 903 patients with stage IB-IIIA non-small cell lung cancer who have had their tumors surgically removed. Half receive nivolumab i…

This study is testing whether adding a drug called durvalumab (an immunotherapy) to standard chemotherapy and radiation works better for treating bladder cancer that has spread to nearby lymph nodes. The main goal is to see if more patients achieve a complete response, meaning no…

This study is testing whether adding a new drug called ipatasertib to an existing hormone therapy (megestrol acetate) is more effective at controlling advanced endometrial cancer that has returned or spread. The trial will first find the safest dose of the combination, then compa…

This study is testing a drug called defactinib for people with advanced cancers that have a specific genetic change called an NF2 mutation. The drug aims to block a protein that these cancer cells may need to grow. Researchers want to see if taking defactinib pills twice a day ca…

This large, late-stage trial is testing whether adding a targeted immunotherapy drug called blinatumomab to standard chemotherapy helps adults with a specific type of acute lymphoblastic leukemia (ALL) live longer. The study involves nearly 500 adults aged 30-70 who are newly dia…

This study tested if adding an experimental drug called cixutumumab to standard chemotherapy (paclitaxel) could better control cancer that had spread or returned. It involved 94 adults with advanced esophageal or gastroesophageal junction cancer whose initial treatment had stoppe…

This large, late-stage trial is comparing two treatment approaches for adults under 70 with untreated chronic lymphocytic leukemia (CLL). One group receives a three-drug combination (ibrutinib, obinutuzumab, and venetoclax) for a limited time. The other group receives two of the …

This study is testing if adding an experimental drug called veliparib to standard chemotherapy and radiation is more effective for people with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if the combination helps patients live longer …

This study is testing a combination of six drugs, called TEDDI-R, to treat aggressive B-cell lymphoma that has spread to the central nervous system (brain, spinal cord, or eyes). The goal is to see if this new regimen can better control the cancer and help patients live longer wi…

This study is testing whether a pill called palbociclib can shrink or stop the growth of advanced cancers that have specific genetic changes (CCND1, 2, or 3 amplification). The drug works by blocking proteins that help cancer cells grow. The trial is for adults with advanced soli…

This large, late-stage trial is testing whether adding a new drug called triapine to the standard treatment of radiation and chemotherapy (cisplatin) works better for women with newly diagnosed, advanced cervical or vaginal cancer. The goal is to see if the three-drug combination…

This study tests whether vorinostat pills can help control metastatic uveal melanoma, a rare and aggressive eye cancer that has spread. Forty patients will take the medication in cycles to see if it shrinks tumors and extends survival. The trial also monitors side effects and exp…

This large, late-stage trial is comparing two chemotherapy programs for children and young adults newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). One group receives the standard, intensive chemotherapy regimen. The other …

This large, late-stage trial is testing whether adding an immunotherapy drug (atezolizumab) to the standard treatment of chemotherapy and radiation improves results for patients with muscle-invasive bladder cancer. The goal is to better control the cancer and help patients keep t…

This study is testing a new oral drug called TRC102 (methoxyamine) to see if it can make tumor cells more sensitive to standard chemotherapy drugs. It is for adults with advanced solid tumors or mesothelioma that have spread or stopped responding to usual treatments. The goal is …

This early-stage study is testing a new oral drug called Triapine, given alongside standard chemotherapy (cisplatin) and radiation for patients with advanced cervical or vaginal cancer. The main goals are to find the safest and most effective dose of Triapine and to see how well …

This early-stage study is testing whether a drug called trametinib can be safely combined with whole brain radiation therapy for patients whose cancer has spread to the brain. The goal is to see if the drug makes the tumor cells more sensitive to the radiation, potentially improv…

This study is testing if adding a new drug called ipatasertib to a standard immunotherapy (pembrolizumab) works better for controlling advanced head and neck cancer that has returned or spread. About 52 patients will be randomly assigned to receive either the two-drug combination…

This study is for older adults newly diagnosed with a type of blood cancer called acute myeloid leukemia (AML) who cannot or choose not to have intensive chemotherapy. It compares two treatment plans: the current standard two-drug combination versus adding a third immunotherapy d…

This study is testing if adding a new drug called berzosertib to a standard three-drug treatment works better for people with advanced squamous cell lung cancer. The goal is to control the cancer, slow its growth, and help patients live longer. Researchers will compare the four-d…

This study is testing whether a combination of two targeted drugs, trastuzumab and pertuzumab, can help control advanced cancers that have a specific genetic change called HER2 amplification. The trial is for patients whose cancers are not breast, stomach, or colorectal cancer, a…

This study is testing whether a combination of two drugs, copanlisib and rituximab, can effectively slow the growth of follicular lymphoma in people who haven't had treatment yet. The goal is to see if this drug pair can produce deep and lasting remissions without using tradition…

This early-phase trial is testing a new way of giving two cancer drugs—olaparib and adavosertib—one after the other instead of together. The goal is to see if this sequence can shrink or stabilize advanced solid tumors that have spread and stopped responding to other treatments, …

This study is testing whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors better than a placebo in people whose cancer has continued to worsen despite prior treatments. About 298 participants with specific advanced neuroendocrine tumors will be ran…

This large study is testing if starting an immunotherapy drug called durvalumab at the same time as standard chemotherapy and radiation is better than the current approach of giving it only after those treatments. It involves 660 adults with stage 3 non-small cell lung cancer tha…

This study is testing whether adding a chemotherapy drug (eribulin) to an immunotherapy drug (atezolizumab) works better than the immunotherapy drug alone for people with advanced bladder cancer that has spread or come back. It is for patients who cannot take a standard chemother…

This large study aimed to find out if giving a key chemotherapy drug (paclitaxel) once a week is better than giving it once every three weeks for treating advanced ovarian, fallopian tube, or primary peritoneal cancer. All participants also received another chemotherapy drug (car…

This large study is testing if a newer immunotherapy drug, pembrolizumab, is better at preventing melanoma from coming back after surgery than the current standard treatments. It involves over 1,300 patients with stage III or IV melanoma who have had their cancer surgically remov…

This study is testing a new combination of three drugs—copanlisib, nivolumab, and ipilimumab—for adults with advanced solid tumors that have spread and have specific genetic changes. The goal is to see if adding copanlisib to two existing immunotherapy drugs is safe and works bet…

This study is testing whether a new HPV vaccine (PRGN-2009) works better when given alongside an immunotherapy drug (pembrolizumab) before patients start their standard cancer treatment. It aims to boost the immune system's attack on the cancer cells. The trial is for adults newl…

This large study is comparing a newer, targeted drug (ibrutinib) plus an antibody (rituximab) against the standard chemotherapy combination for younger adults with untreated chronic lymphocytic leukemia (CLL). The goal is to see which approach keeps the cancer from getting worse …

This early-stage trial tests the safety of a new cell therapy for adults with multiple myeloma that hasn't responded to standard treatments. Doctors collect a patient's own immune cells, genetically modify them in a lab to better recognize cancer, and infuse them back after chemo…

This study is for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer, that has stopped responding to standard immunotherapy. It aims to see if adding a new drug called tuvusertib to an existing immunotherapy (avelumab) can help control the cancer for lo…

This early-stage study aims to find safe doses of a three-drug combination for treating advanced solid tumors in patients who also have kidney or liver problems. Researchers are testing a new drug called veliparib, given with two standard chemotherapy drugs, to see how the body p…

This early-stage study is testing whether a combination of five existing drugs is safe for people with aggressive lymphoma that has spread to the brain or spinal cord. The trial will enroll about 14 adults whose cancer has returned after prior treatment or who cannot receive stan…

This study is testing an oral drug called MLN0128 (TAK-228) in patients with advanced or hard-to-treat cancers that have specific genetic changes called mTOR mutations. The drug is designed to block a key enzyme that cancer cells need to grow. The goal is to see if the drug can s…

This early-stage study is testing the safety and best dose of an experimental drug called berzosertib when given alongside standard whole brain radiation therapy. The goal is to see if the drug combination works better than standard care to control cancer that has spread from the…

This study is testing a combination of two oral medications, olaparib and cediranib, for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned after previous treatment. The goal is to see if taking these two drugs together can slow or stop cancer growth b…

This large, late-stage trial is testing whether adding the drugs bortezomib or sorafenib to standard chemotherapy can better control acute myeloid leukemia (AML) in children and young adults. It focuses on patients with a specific high-risk genetic feature called FLT3/ITD. The st…

This study is testing whether the drug ibrutinib can help control advanced skin melanoma that has continued to grow despite previous standard treatments. It will involve about 18 adults whose cancer has spread and is no longer responding to immunotherapy or other targeted drugs. …

This study tested whether adding a drug called interferon-alpha to the immunotherapy ipilimumab works better than ipilimumab alone for people with advanced melanoma that cannot be removed by surgery. It involved 88 participants and compared different doses and combinations to see…

This study is testing whether the drug crizotinib can help people with advanced cancers that have a specific genetic change called a ROS1 translocation. The drug aims to block a protein that these cancer cells need to grow. Researchers want to see if taking crizotinib daily can s…

This early-stage study is testing a new drug called birinapant, given alongside a precise form of radiation therapy, for people whose head or neck cancer has come back in the same area. The main goals are to find the safest dose of the drug and understand its side effects when co…

This study aims to find the most effective drug combination for treating advanced or returning endometrial (uterine) cancer. It randomly assigned 349 patients to receive one of three different chemotherapy and targeted drug regimens. Researchers are comparing how well each combin…

This early-stage trial is testing a new therapeutic vaccine designed to fight cancers caused by the human papillomavirus (HPV). Researchers want to see if the vaccine works better when given alone or combined with an immunotherapy drug called M7824. The study includes adults with…

This large study is testing if adding a drug called atezolizumab, which helps the body's immune system fight cancer, to standard chemotherapy works better than chemotherapy alone. It's for patients with stage III colon cancer that has been surgically removed but has a high risk o…

This large, late-stage trial is testing whether a one-year course of the immunotherapy drug pembrolizumab can help prevent cancer from returning in patients with high-risk triple-negative breast cancer. The study involves over 1,100 patients whose cancer showed significant remain…

This study is testing whether a drug called ado-trastuzumab emtansine can shrink or stop the growth of advanced cancers that have a specific genetic change called HER2 amplification. The trial is for patients with various hard-to-treat cancers (like lymphoma and solid tumors), bu…

This study is testing a combination of two oral drugs, mirdametinib and sirolimus, for people with advanced multiple myeloma that has returned or stopped responding to many other treatments and has specific genetic changes (KRAS or NRAS mutations). The goal is to find a safe dose…

This study is testing whether a transplant of healthy blood-forming stem cells from a donor can safely give people with serious T-cell immune disorders a new, working immune system. The goal is to control these often life-threatening conditions by replacing the faulty immune cell…

This early-stage study is testing the safety and best dose of two drugs, veliparib and dinaciclib, when given together to patients with advanced solid tumors that have spread. The main goal is to find out what side effects occur and determine a safe dose for future testing. The d…

This early-stage study is testing the safety and best dose of a new oral drug (MLN0128) when combined with an existing cancer drug (bevacizumab). It is for adults with recurrent glioblastoma (a type of brain tumor) or other advanced solid tumors that have not responded to standar…

This study is testing how well a drug called selpercatinib works for children and young adults with advanced or hard-to-treat cancers that have a specific genetic change in the RET gene. The drug is designed to block the growth of cancer cells with this change. Participants take …

This study is testing whether adding a drug called veliparib to a standard two-drug chemotherapy regimen works better for treating advanced blood cancers. It involves 25 adults with specific types of leukemia and related disorders that have progressed or are hard to treat. Partic…

This study is for people with follicular lymphoma, a type of blood cancer, that has come back early or did not respond to their first treatment. It compares three different drug combinations to see which works best to control the cancer. One group gets a standard chemotherapy mix…

This study is for people with a specific type of advanced small cell lung cancer. It tests if adding a daily pill (talazoparib) to a standard immunotherapy drug (atezolizumab) is better at keeping the cancer from growing or spreading than the immunotherapy drug alone. The goal is…

This study is testing whether a drug called copanlisib can help control advanced cancers that have a specific change in a gene called PTEN. The drug is given through an IV and aims to block signals that tell cancer cells to grow. It is for adults with various advanced or hard-to-…

This early-stage study is testing a new combination of three drugs—navtemadlin, decitabine, and venetoclax—for adults with acute myeloid leukemia (AML). The main goals are to find the safest dose and understand the side effects. The hope is that using all three drugs together wil…

This study is testing whether a pill called afatinib can help control advanced cancers that have a specific genetic change (EGFR mutation) and have stopped responding to standard treatments. It is for adults with various solid tumors or lymphomas (but not lung cancer or certain b…

This early-stage study is testing the safety and best dose of a two-drug combination for patients with advanced myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The trial combines a chemotherapy drug (decitabine…

This study is testing whether a pill called selumetinib works as well as or better than standard intravenous chemotherapy (carboplatin/vincristine) for children and young adults with low-grade brain tumors linked to Neurofibromatosis Type 1 (NF1). The main goals are to see which …

This study tested a drug called selumetinib for children and young adults whose low-grade brain tumors have returned or stopped responding to treatment. The goal was to find a safe dose and see if the drug could shrink or control the tumors. Participants took the drug orally in r…

This large, late-stage trial is testing if adding the immunotherapy drug nivolumab to standard chemotherapy and immunotherapy helps patients with a specific type of lymphoma live longer without their cancer getting worse. It involves 244 patients aged 2 and older who are newly di…

This large study aimed to find the best drug treatment to prevent melanoma skin cancer from coming back after it has been surgically removed. It compared a newer immunotherapy drug (ipilimumab) against a standard treatment (interferon) in over 1,600 patients with high-risk melano…

This is an early-stage safety study testing a new drug called BAY 1895344 when given with standard chemotherapy drugs (cisplatin with or without gemcitabine). The main goals are to find the safest dose and understand the side effects in people with advanced solid tumors that have…

This early-stage trial is testing a new hormone therapy called Z-Endoxifen in women whose estrogen-positive breast cancer has returned or spread. The main goals are to find the safest dose and understand the drug's side effects. Participants take the drug daily in 28-day cycles w…

This study tested a personalized approach for treating advanced lung cancer that had stopped responding to standard drugs. Doctors analyzed each patient's specific tumor mutations and assigned them to one of several targeted drug combinations or chemotherapy. The goal was to see …

This early-stage study is testing the safety and best dose of a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has come back or stopped responding to other treatments. The goal is to see if this drug pair can help control the cancer and is sa…

This study is testing whether the drug crizotinib can help control advanced cancers that have a specific genetic change called a MET exon 14 deletion. It is for patients with solid tumors, lymphoma, or multiple myeloma that have stopped responding to other treatments. Participant…

This study is testing whether Radium-223, a radioactive drug, can help men whose prostate cancer has returned but is only detectable through special PET scans, not standard imaging. Participants receive up to six monthly injections while researchers monitor changes in their immun…

This study is testing whether starting a drug called lenalidomide early can delay or prevent the progression of a pre-cancerous blood condition (high-risk smoldering myeloma) to active cancer. It compares the drug to a 'watch and wait' approach in over 200 patients. The main goal…

This study is testing an experimental drug called AZD5363 in patients with advanced cancers that have a specific genetic change called an AKT mutation. The drug is designed to block the AKT protein, which cancer cells need to grow. Researchers want to see if taking this pill can …

This early-stage trial aims to find the safest and most effective dose of two drugs—cyclophosphamide and veliparib—when given together. It is for people with advanced breast cancer that has spread and is HER2-negative. The main goal is to understand the side effects and determine…

This early-stage study aims to find the safest and most effective dose of two drugs—trastuzumab deruxtecan and neratinib—when used together. It is for adults with advanced solid tumors that have spread or cannot be removed by surgery and have specific changes in the HER2 gene. Th…

This study aims to find the best drug combination to control recurrent ovarian cancer that has stopped responding to standard platinum-based chemotherapy. It is testing a chemotherapy drug (pegylated liposomal doxorubicin) alone or combined with one or two immunotherapy drugs (at…

This early-stage trial is testing whether adding a new oral drug called selinexor to the standard treatment of radiation and chemotherapy (temozolomide) is safe for people newly diagnosed with glioblastoma, a fast-growing brain cancer. The main goal is to find the highest dose of…

This study is testing an experimental drug called dinaciclib in people with stage IV melanoma, a serious form of skin cancer that has spread. The main goal is to see if the drug helps patients live longer by stopping cancer cell growth. Researchers will also track how well tumors…

This early-stage study is testing the safety of a drug called atezolizumab in cancer patients who have already received a special immune cell therapy. The goal is to see if this drug can help the transferred immune cells work better against the cancer. The study will enroll about…

This early-stage study is testing a new oral drug, M3814, when given alongside a standard chemotherapy regimen (MEC) for adults with acute myeloid leukemia (AML) that has come back or is not responding to other treatments. The main goals are to find the safest and most effective …

This early-phase trial is testing the safety and best dose of a two-drug combination for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The study is for patients whose cancer has continued to grow despite trying standard chemothera…

This early-stage study aims to find the safest and most effective dose of two drugs, ixabepilone and temsirolimus, when given together to adults with advanced solid tumors that have spread or cannot be surgically removed. The main goal is to understand the side effects and determ…

This study tested adding a drug called vorinostat to standard chemotherapy (R-CHOP) for people newly diagnosed with advanced diffuse large B-cell lymphoma. The goal was to see if the combination is safe, find the right dose, and check if it helps patients live longer without thei…

This early-stage trial is testing a new combination of two drugs, veliparib and carboplatin, for people with advanced HER2-negative breast cancer that has spread. The main goals are to find the safest and most effective dose and to understand the side effects. Researchers hope th…

This study is for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (ALL) called BCR-ABL-positive. It compares the current standard treatment (chemotherapy plus targeted pills) against a newer approach that swaps some chemotherapy for an immunotherapy dr…

This study is testing whether combining two drugs, trametinib and docetaxel, can help control advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation. It is for patients whose cancer has continued to grow despite one or two prior treatments. …

This study is testing a combination of two drugs, cetuximab and interleukin-12 (IL-12), for people with advanced head and neck cancer that has returned, spread, or cannot be surgically removed. The first goal is to find a safe dose of IL-12 to use with cetuximab. The second goal …

This study is testing whether a combination of three existing drugs can shrink or stop the growth of a rare type of ovarian cancer that has come back after prior treatment. The drugs work together to block different hormones that the tumor cells need to grow. The trial will enrol…

This study is testing whether two oral drugs, olaparib and ceralasertib, can help control advanced cancers that have a specific genetic change called an IDH mutation. It is for adults whose cancer has grown despite standard treatments. The main goal is to see if the drug combinat…

This study tested an oral drug called selumetinib in children and young adults with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas—nerve tumors that cannot be safely removed by surgery. The goal was to see if the drug could shrink these tumors or stop them from g…

This early-stage trial is testing a combination of two oral drugs, sapanisertib and telaglenastat, in patients with advanced non-small cell lung cancer that has spread and stopped responding to standard treatments. The main goals are to find the safest and most effective dose and…

This study is testing a combination of three immunotherapy drugs for people with advanced cancers that have not responded well to standard treatments. It focuses on HPV-related cancers (like cervical, throat, and anal cancers) and certain types of colon and small bowel cancer. Th…

This early-stage study is testing the safety and best dose of a new two-drug combination (ZEN003694 and binimetinib) for people with advanced solid tumors that have specific genetic changes. The main goal is to see what side effects occur and find a dose that is safe for future t…

This study is testing a drug called adavosertib in people with advanced solid tumors that have spread and have a specific genetic change called SETD2 deficiency. The goal is to see if the drug can shrink or stop the growth of these tumors by blocking enzymes the cancer cells need…

This study is testing a drug called sunitinib in patients with advanced cancers that have a specific change (mutation) in a gene called cKIT. The drug aims to block the faulty signal from this mutated gene that tells cancer cells to grow, which could help slow or stop the cancer'…

This large, late-stage trial is testing whether taking pills (olaparib alone or with cediranib) works as well or better than standard intravenous chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned but still responds to platinum drugs. …

This study is testing whether the immunotherapy drug avelumab is safe and can help control thymoma or thymic carcinoma that has grown or returned after standard platinum-based chemotherapy. It involves 56 adults who will receive avelumab by IV infusion every two weeks until side …

This study is testing an experimental pill called telaglenastat in adults with advanced solid tumors that have spread or cannot be removed by surgery. The pill works by blocking a nutrient (glutamine) that some cancer cells with specific genetic mutations need to grow. The goal i…

This early-stage study is testing a combination of three drugs—alisertib, bortezomib, and rituximab—in patients whose mantle cell or low-grade B-cell lymphoma has returned or stopped responding to other treatments. The main goal is to find the safest and most effective doses of t…

This study is testing if a combination of two drugs works better than one alone to control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It compares a standard targeted drug (olaparib) against that same drug plus an immunotherapy drug (tremelimumab). The main g…

This large study aims to find the most effective and safest combination of chemotherapy drugs for children and young adults newly diagnosed with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It tests different drug regimens, including one that adds a targeted drug (dasat…

This study is testing if adding a drug called olaparib to standard chemotherapy (temozolomide) works better to control advanced adrenal gland tumors (pheochromocytoma and paraganglioma) that have spread or cannot be removed by surgery. It will involve about 46 patients aged 12 an…

This early-phase study aimed to test the safety and find the right dose of a two-drug immunotherapy (nivolumab and ipilimumab) for children, teens, and young adults whose cancers had returned or stopped responding to standard treatments. The drugs work by helping the patient's ow…

This study is testing whether adding a third drug, navitoclax, to two existing melanoma drugs (dabrafenib and trametinib) can help shrink tumors more effectively. It involves adults with advanced, BRAF-mutant melanoma or other solid tumors that have spread or cannot be removed by…

This study aims to find the most effective drug combination for treating higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), which are serious blood and bone marrow disorders. Researchers are comparing a standard chemotherapy drug (azacitidine)…

This study is testing a two-part treatment for soft tissue sarcoma before surgery. First, a modified cold sore virus (T-VEC) is injected into the tumor to help the immune system attack it. Then, patients receive radiation therapy. The goal is to kill as much of the tumor as possi…

This study is testing an oral drug called MLN0128 (TAK-228) in patients with advanced cancers that have stopped responding to other treatments. The drug is specifically for patients whose tumors have certain genetic changes called TSC1 or TSC2 mutations. The goal is to see if blo…

This study is testing whether adding a new drug called uproleselan to standard chemotherapy helps older adults with acute myeloid leukemia (AML) live longer and stay in remission. Researchers are comparing the standard two-drug chemotherapy to the same chemotherapy plus uprolesel…

This large, late-stage trial is comparing two different drug combination strategies to control advanced kidney cancer that has spread. It involves over 1,100 patients with intermediate or high-risk disease. The study aims to see if adding a drug called cabozantinib to a standard …

This early-stage trial is testing a new type of cell therapy for children and young adults whose neuroblastoma or osteosarcoma has returned or not responded to standard treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab to recognize a specific p…

This study is testing a two-part treatment for patients with stage II or III non-small cell lung cancer who are not candidates for surgery or standard chemo-radiation. First, patients receive a shorter, more intense course of radiation over three weeks. Then, they receive an immu…

This study is testing whether the drug taselisib can shrink or stop the growth of advanced cancers that have a specific genetic change called a PIK3CA mutation. It is for patients whose cancer has not responded to standard treatments. The goal is to see if blocking the faulty PIK…

This study is testing an experimental pill called M1774 for men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and has stopped responding to standard treatments. The pill aims to block a protein that cancer cells need to grow, potentially shrinki…

This study is testing whether adding a new drug called copanlisib to a standard chemotherapy (eribulin) is safe and more effective for treating advanced triple-negative breast cancer that has spread. It will involve about 24 patients whose cancer has progressed after prior treatm…

This study is testing if a lower dose of radiation combined with an immunotherapy drug (nivolumab) works as well as the standard, higher-dose radiation combined with chemotherapy (cisplatin) for treating early-stage throat cancer linked to HPV in non-smokers. The goal is to contr…

This study is testing an experimental drug called bintrafusp alfa (M7824) for people with thymoma or thymic carcinoma that has returned or worsened after standard platinum-based chemotherapy. The drug is designed to work in two ways: by blocking a protein that helps tumors hide f…

This early-stage study is testing a new combination of two drugs, sapanisertib and osimertinib, for people with advanced non-small cell lung cancer. The cancer must have a specific genetic change (EGFR mutation) and has gotten worse after treatment with a standard targeted drug. …

This early-stage trial is testing a combination of two drugs, ibrutinib and palbociclib, for people with mantle cell lymphoma that has returned after prior treatment. The main goal is to find the safest and most effective dose of the two drugs taken together. Researchers hope tha…

This early-stage study is testing if a three-part treatment plan is safe and feasible for people with operable pleural mesothelioma, a cancer often linked to asbestos exposure. The plan involves chemotherapy plus an immunotherapy drug before surgery, followed by up to a year of t…

This large study is testing whether taking a daily pill called erlotinib for two years after lung cancer surgery helps patients live longer. It compares the pill to just regular check-ups (observation) in patients whose cancer has a specific genetic change (EGFR mutation). The go…

This study tested whether taking a daily pill called lenalidomide after a stem cell transplant could help patients with multiple myeloma live longer without their cancer getting worse. About 460 patients who had their own stem cells transplanted were randomly assigned to receive …

This large, late-stage trial is testing whether adding the drug bevacizumab to standard chemotherapy helps patients with advanced head and neck cancer that has returned or spread. The study enrolled 403 participants to see if the combination helps people live longer or slows canc…

This study is testing whether adding an immunotherapy drug (atezolizumab) to a precise form of radiation therapy works better than radiation alone for people with early-stage, non-small cell lung cancer who cannot have surgery. The goal is to see if the combination helps patients…

This early-stage trial is testing a new type of CAR-T cell therapy designed to fight B-cell cancers like leukemia and lymphoma. The therapy modifies a patient's own immune T-cells to hunt and kill cancer cells by targeting two proteins (CD19 and CD20) on the cancer's surface. The…

This study is testing whether using lower doses of a key drug (cyclophosphamide) and for a shorter time after a stem cell transplant can reduce side effects while still preventing a dangerous complication called graft-versus-host disease (GVHD). It involves people ages 15-65 with…

This early-stage trial is testing the safety and initial effectiveness of combining two anti-cancer drugs, pomalidomide and liposomal doxorubicin, for people with advanced or hard-to-treat Kaposi sarcoma (KS). The study involves 62 adults with KS, including those with HIV, who re…

This study tested if adding a new drug called cediranib to standard chemotherapy (cisplatin and pemetrexed) works better for people with malignant pleural mesothelioma, a serious cancer often linked to asbestos. The trial had two parts: first to find a safe dose of cediranib, the…

This is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…

This study is testing whether a combination of two oral drugs, talazoparib and temozolomide, can shrink advanced rare cancers that have spread and for which standard treatments have stopped working. The trial aims to see if this drug pair can stop tumor growth by damaging cancer …

This study is for people with advanced uterine leiomyosarcoma, a type of cancer, that has continued to grow despite at least two prior chemotherapy treatments. It compares a new combination of two oral drugs, olaparib and temozolomide, against the current standard chemotherapy op…

This study is testing if a new drug called Briquilimab can make stem cell transplants safer for people with GATA2 deficiency, a genetic disorder that weakens the immune system and can lead to blood cancers. Participants receive Briquilimab as part of their preparation for a trans…

This study is for adults 65 and older with untreated chronic lymphocytic leukemia (CLL), a type of blood cancer. It compares the standard two-drug treatment (ibrutinib + obinutuzumab) against an experimental three-drug combination that adds a medication called venetoclax. The mai…

This study aims to understand and treat a rare, often fatal disorder called KSHV-associated multicentric Castleman's disease, which is caused by a virus and linked to certain cancers. Researchers are testing several experimental drug combinations in 75 adult participants to see i…

This large, late-stage trial is testing whether adding a new drug called entinostat to standard hormone therapy (exemestane) works better than the hormone therapy alone. It's for people whose hormone-sensitive, advanced breast cancer has continued to grow despite prior treatment.…

This study is testing whether the drug vismodegib can help control advanced cancers that have specific genetic mutations and have stopped responding to standard treatments. The trial includes 35 adults with solid tumors, lymphoma, or multiple myeloma that have spread or are resis…

This early-stage study is testing the safety and best doses of a combination of two or three drugs (vismodegib, erlotinib, and sometimes gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The goal is to see if blocking …

This large, late-stage trial is comparing two treatment strategies for advanced colorectal cancer that has a specific genetic feature (dMMR/MSI-H). One group receives a single immunotherapy drug (atezolizumab), while another gets that same drug combined with standard chemotherapy…

This study is testing a drug called tipifarnib in children and young adults whose advanced cancers have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug as a pill or through a fee…

This study tested whether taking a drug called pazopanib for about a year could help keep kidney cancer from returning after surgeons had successfully removed all visible tumors that had spread. Patients who had no signs of cancer left after surgery were randomly assigned to take…

This study is testing an experimental pill called GSK2636771 for people with advanced cancers that have stopped responding to other treatments and have a specific genetic change called a PTEN mutation. The pill is designed to block a protein that these cancer cells may need to gr…

This study is comparing two treatment approaches for patients with a specific type of stomach or gastroesophageal junction cancer that has not spread widely. The goal is to see if using an immunotherapy drug (atezolizumab) combined with chemotherapy before and after surgery works…

This study is testing a pill called trametinib for people with advanced cancers that have stopped responding to other treatments and have specific changes in a gene called BRAF. The pill aims to block proteins that these cancer cells need to grow. Researchers want to see if the t…

This study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…

This study is testing whether a drug called copanlisib can shrink or stop the growth of advanced cancers that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that cancer cells need to grow. The trial includes 35 adults with various ad…

This early-stage study aims to find the safest and most effective dose of a new drug, M6620, when given with the chemotherapy drug irinotecan. It is for adults with advanced solid tumors, like certain colorectal, pancreatic, or lung cancers, that have spread or cannot be removed …

This early-stage trial is testing the safety and best dose of a two-drug combination for people with a specific type of advanced lung cancer. The study is for adults whose EGFR-mutant non-small cell lung cancer has continued to grow despite prior targeted therapy. Researchers wan…

This study is testing the safety and effectiveness of combining two drugs, vorinostat and azacitidine, for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination can better control the disease by…

This study tested a multi-part treatment for adults with a specific, aggressive type of acute lymphoblastic leukemia (ALL). The goal was to see if combining intensive chemotherapy, a targeted drug called dasatinib, and for some patients, a stem cell transplant from a donor, could…

This study is testing whether adding the drug ibrutinib to a stem cell transplant helps patients with a specific aggressive lymphoma that has returned or not responded to prior treatment. Patients receive either ibrutinib or a placebo (inactive pill) before and for a year after t…

This study is testing if adding a new oral drug called triapine to a standard radioactive treatment (Lu-177 dotatate) works better to shrink or slow the growth of advanced neuroendocrine tumors that have spread. It will compare the two-drug combination against the standard single…

This early-stage study is testing a new combination of two drugs for people with advanced neuroendocrine tumors that have spread. The goal is to find the safest and most effective dose by giving patients an oral drug (triapine) alongside a targeted radiation therapy (lutetium Lu …

This large, late-stage trial is comparing a new immunotherapy drug called blinatumomab against standard chemotherapy for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has returned after initial treatment. The study aims to see if using the body's own…

This study is for people with advanced non-small cell lung cancer that has low levels of a marker called PD-L1. It compares the standard immunotherapy treatment (with or without chemo) to the same treatment plus a short course of radiation. The goal is to see if adding radiation …

This early-stage study is testing a new combination of drugs for people with advanced solid tumors or non-Hodgkin lymphoma that has spread. The main goal is to find the safest and most effective dose by combining an experimental drug called veliparib with standard chemotherapy dr…

This early-stage trial is testing whether a radioactive antibody called lintuzumab-Ac225 can help control advanced myelodysplastic syndrome (MDS) that hasn't responded to standard treatments. The treatment works by attaching to cancer cells and delivering radiation directly to th…

This early-phase trial is testing the safety and best dose of a new oral drug, ZEN003694, when given with standard immunotherapy drugs (nivolumab with or without ipilimumab) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see…

This study is testing a daily pill called ibrutinib for people with hairy cell leukemia that has returned after previous treatment. The goal is to see if the drug can control the cancer by blocking a protein that helps the cancer cells grow. Researchers will measure how well pati…

This study is for children and young adults whose low-grade brain tumor has come back or stopped responding to treatment. It aims to find out if combining two drugs, selumetinib and vinblastine, works better than using selumetinib alone to control the tumor and prevent it from gr…

This early-stage study is testing the safety and best dose of a two-drug combination (dabrafenib and lapatinib) for adults with advanced thyroid cancer that has a specific genetic change (BRAF mutation) and has stopped responding to standard treatments. The main goal is to see ho…

This study is testing whether adding an immunotherapy drug (atezolizumab) to a targeted cancer drug (olaparib) works better than the targeted drug alone for people with advanced breast cancer that has a specific genetic flaw (BRCA mutation). The goal is to see if the combination …

This study is testing a new combination treatment for glioblastoma, an aggressive brain cancer that has returned after initial therapy. It combines two immunotherapy drugs (tocilizumab and atezolizumab) with a precise form of radiation. The goal is to see if this three-part appro…

This study is for children and young adults (up to age 40) with intermediate-risk rhabdomyosarcoma, a type of muscle cancer. It compares the current standard chemotherapy to the same chemotherapy plus a newer drug called temsirolimus. The goal is to see if adding temsirolimus hel…

This study is testing if adding an immunotherapy drug (pembrolizumab) to a standard chemotherapy (gemcitabine) can better control a specific type of early-stage bladder cancer. The cancer in these patients has not responded to the usual first-line treatment (BCG). The goal is to …

This study is for people with intermediate-risk, HPV-positive throat cancer that has spread to nearby lymph nodes. After finishing standard treatment with chemotherapy and radiation, patients are randomly assigned to either receive a year of an immunotherapy drug (nivolumab) or t…

This study is testing whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation can better treat certain cancers of the esophagus and stomach junction. It involves patients who are scheduled for surgery. The goal is to see if this co…

This study is testing whether combining two drugs, olaparib and temozolomide, can help control advanced uterine leiomyosarcoma, a rare and aggressive cancer. It is for patients whose cancer has spread or cannot be removed by surgery and who have already tried at least one other t…

This study is testing a drug called trametinib for people with advanced cancers that have a specific genetic change called an NF1 mutation. The drug works by blocking proteins that these cancer cells may need to grow. Researchers want to see if trametinib can shrink these tumors …

This early-stage study is testing a new combination of two immunotherapy drugs, pembrolizumab and interleukin-12, for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and understand the side effects. Re…

This study tested whether adding a drug called GM-CSF (sargramostim) to an existing immune-boosting cancer drug (ipilimumab) could help patients with advanced melanoma live longer. The trial involved 245 adults whose melanoma could not be removed by surgery. Researchers compared …

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, to treat older adults with a type of blood cancer called acute myeloid leukemia (AML). The goal was to see if this combination was safe and effective enough to put patients into remission and war…

This early-stage trial is testing a new drug called peposertib combined with radiation therapy for patients with advanced head and neck cancer who cannot take the standard chemotherapy drug cisplatin. The main goals are to find the safest and most effective dose of peposertib and…

This study is testing whether combining two drugs, olaparib and cediranib, is more effective than using olaparib alone for men with advanced prostate cancer that has stopped responding to standard hormone therapy and has spread. The trial aims to see if the drug combo can better …

This large Phase 3 trial compares two different drug combinations for people newly diagnosed with multiple myeloma, a type of blood cancer. It tests whether adding a drug called bortezomib to a standard two-drug regimen (lenalidomide and dexamethasone) works better at controlling…

This study aimed to test an experimental drug called CBX-12 for people with advanced colorectal cancer that had spread and was no longer responding to standard chemotherapy. The drug was designed to deliver a cancer-killing agent directly into tumor cells. The trial was withdrawn…

This study tested a daily pill called ibrutinib in 41 patients with follicular lymphoma, a type of blood cancer, that had returned or stopped responding to previous treatments. The main goal was to see how well the drug could shrink the cancer and control the disease. Researchers…

This large, late-stage trial is testing if adding a targeted drug called brentuximab vedotin to standard chemotherapy works better than chemotherapy alone for children and young adults with newly diagnosed, high-risk Hodgkin lymphoma. The study aims to see if the new combination …

This study is for people with advanced melanoma that has a specific BRAF gene mutation and cannot be removed by surgery. It is testing which order of two powerful treatment combinations leads to longer survival. One group starts with immunotherapy (ipilimumab + nivolumab) and swi…

This early-stage study is testing a new oral drug called IPdR (ropidoxuridine) in combination with standard whole-brain radiation therapy. The goal is to see if the drug makes cancer cells in the brain more sensitive to radiation, potentially improving treatment for patients whos…

This early-stage study is testing the safety and best dose of a new drug called ipatasertib when given alongside standard chemotherapy drugs (paclitaxel and carboplatin) to patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if adding …

This study is testing whether adding a new drug called selinexor to standard chemotherapy (temozolomide) works better than the standard chemotherapy alone for glioblastoma brain cancer that has returned. The trial first finds the safest dose of the combination, then compares how …

This study is testing whether the drug erdafitinib can help control advanced solid tumors that have specific genetic changes called FGFR mutations or fusions. The drug works by blocking a faulty protein that tells cancer cells to grow. The trial enrolled 35 adults whose cancer ha…

This study is testing whether adding a new targeted drug (anetumab ravtansine) to an existing immunotherapy (pembrolizumab) works better than the immunotherapy alone for treating advanced pleural mesothelioma. The trial aims to see if the combination is safe and more effective at…

This study aimed to test a new combination treatment for advanced colon cancer that has spread and is resistant to standard immunotherapies. It planned to give patients two immunotherapy drugs (tiragolumab and atezolizumab) along with a short, targeted course of radiation. The go…

This study is testing if adding a new drug called copanlisib to the standard two-drug treatment (fulvestrant and abemaciclib) is more effective for advanced breast cancer that has stopped responding to hormone therapy. It will involve about 24 patients with hormone-positive, HER2…

This large, late-stage trial is testing a new treatment approach for children with a rare liver cancer called hepatoblastoma. The study aims to improve survival and reduce side effects by giving different treatments based on how advanced the cancer is. For children with the highe…

This is an early-stage safety study testing a new type of DNA vaccine designed to help the body's immune system fight chronic Hepatitis C virus (HCV) infection. The trial will enroll 33 adults with a specific type of HCV (genotype 1) to determine safe doses and see if the vaccine…

This study tested an oral drug called vismodegib in patients with advanced chondrosarcoma, a rare type of bone cancer that has spread and is difficult to treat. The main goal was to see if the drug could stop the cancer from growing for at least six months. Researchers also track…

This study is testing a targeted drug called erdafitinib in patients with advanced cancers that have a specific genetic change (FGFR amplification). The drug works by blocking a faulty protein that tells cancer cells to grow. The trial aims to see if the drug can shrink tumors or…

This early-stage study aims to find the safest and most effective dose of the drug lenalidomide when given alongside a standard chemotherapy regimen (called EPOCH) for adult T-cell leukemia/lymphoma (ATLL), a rare and aggressive cancer. It will involve about 30 adults with ATLL t…

This study is testing whether a drug called obeticholic acid (OCA), already approved for a liver disease, can safely reduce the number of intestinal polyps in people with familial adenomatous polyposis (FAP). FAP is a genetic condition that causes many polyps to grow in the gut, …

This early-stage trial is testing whether combining an experimental cancer drug called MK-2206 with the malaria drug hydroxychloroquine is safe for people with advanced solid tumors, melanoma, kidney, or prostate cancer. The main goal is to find the highest dose patients can tole…

This large Phase 3 trial aims to find the better treatment combination for newly diagnosed advanced Hodgkin lymphoma. It compares adding either nivolumab or brentuximab vedotin to standard chemotherapy. The study will measure which combination keeps the cancer from returning long…

This study tested a new combination of two drugs, entinostat and aldesleukin, for patients with advanced kidney cancer that has spread. The goal was to find a safe dose and see if the combination could help control the cancer better than one drug alone. It involved 47 patients an…

This study is testing whether adding a drug called selinexor to a standard three-drug combination works better for people with high-risk, newly diagnosed multiple myeloma. It will compare the new four-drug combination (Dara-SVD) against the current standard four-drug treatment (D…

This study is comparing two different timing strategies for an immunotherapy drug called pembrolizumab in patients with high-risk melanoma that can be surgically removed. It aims to see if giving the drug *before* surgery (to shrink the tumor) works better than the standard appro…

This large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …

This study is testing if adding a drug called pomalidomide to standard chemotherapy works better for adults newly diagnosed with a specific, harder-to-treat type of acute myeloid leukemia (AML). About 50 participants will be randomly assigned to receive either the standard chemo …

This study tested a two-drug combination (veliparib and topotecan) for people with advanced solid tumors or ovarian cancer that has come back after initial treatment. The first phase aimed to find the safest and most effective dose. The second phase focused on seeing if the combi…

This early-stage study is testing the safety and best doses of a combination of cancer drugs for people with advanced cancers of the urinary system (like bladder and kidney cancer) that have spread. The trial combines a pill (cabozantinib) that aims to block tumor growth with one…

This study is testing an oral medication called tazemetostat for people whose ovarian or endometrial cancer has returned after previous treatments. The drug aims to stop cancer cell growth and shrink tumors. Researchers are enrolling 62 patients to see how well the treatment work…

This study is testing whether adding a radioactive drug called Radium-223 to standard chemotherapy (paclitaxel) works better for people with breast cancer that has spread to their bones. The radioactive drug travels to the bones and aims to kill cancer cells there, potentially sl…

This study is testing a new combination of two drugs, tazemetostat and pembrolizumab, for people with advanced bladder cancer that has spread or is resistant to standard chemotherapy. The main goals are to find the safest dose and see if the combination helps control the cancer b…

This early-stage study is testing a combination of two chemotherapy drugs, vorinostat and temozolomide, in adults with aggressive brain tumors called malignant gliomas. The main goals are to find the safest dose of the drug combination and to understand its side effects. Research…

This early-stage trial is testing a new three-drug combination for people with multiple myeloma that has come back or stopped responding to previous treatments. The main goal is to find the safest and most effective dose of a new experimental drug, CB-839, when given with two exi…

This large study is testing if adding a targeted immunotherapy drug called blinatumomab to standard chemotherapy works better for children and young adults with newly diagnosed B-cell leukemia or lymphoma, including those with Down syndrome. It aims to see if this combination hel…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This study is testing whether the drug olaparib can help control advanced cancers that have a specific genetic change (IDH1 or IDH2 mutation) and have stopped responding to standard treatments. It is enrolling adults with certain brain tumors, bile duct cancer, or other solid tum…

This early-stage trial is testing whether adding an experimental drug called berzosertib to standard radiation therapy can better control breast cancer that has not responded well to chemotherapy. The main goal is to find the safest and most effective dose of the drug when given …

This study is testing if adding an oral drug called trametinib can make radioactive iodine treatment work again for people with advanced thyroid cancer that has spread or come back and no longer responds to iodine. The goal is to see if trametinib helps the cancer absorb more iod…

This study is testing if the drug trametinib can help control advanced cancers that have specific genetic changes called GNAQ or GNA11 mutations. It is for patients with various cancers, including solid tumors and lymphomas, that have not responded to other treatments. The goal i…

This is an early-stage study to find the safest and most effective doses of two cancer drugs, erlotinib and irinotecan, when used together. It involves about 60 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to understand…

This study is testing whether combining two drugs, atezolizumab and cobimetinib, can help control advanced non-small cell lung cancer that has spread or returned and has stopped responding to a common type of immunotherapy. The trial aims to see if this combination can shrink tum…

This large study tested whether adding the drug bevacizumab to standard chemotherapy helps prevent breast cancer from returning after surgery. It involved nearly 5,000 patients with breast cancer that had spread to lymph nodes or was at high risk of coming back. The goal was to s…

This was an early safety study for an experimental cancer drug called CB-5339. It was designed to find the safest dose and check for side effects in adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The study was withdrawn by the s…

This study is testing whether adding a second drug (GSK2141795) to an existing cancer medication (trametinib) works better for controlling advanced uveal melanoma, a rare cancer that starts in the eye and has spread. It enrolled 42 patients who had not received prior drug treatme…

This study is testing if a drug called bevacizumab can help adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants, who currently need surgery multiple times a year to clear these growths, will receive bevac…

This study is testing if giving a low-dose cancer drug (lenalidomide) along with a standard pneumonia vaccine can help the body's immune system better recognize and attack early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It enrolled 49 adults wi…

This study is testing whether the immunotherapy drug nivolumab can help control the growth of certain brain tumors (gliomas) that have specific genetic changes. It is enrolling 62 adults whose tumors have either a very high number of mutations or a normal number. The main goal is…

This study is testing whether a combination of three immunotherapy drugs, with or without a targeted liver procedure called TACE, can help control advanced liver cancer. The goal is to see if this approach can stop the cancer from getting worse for at least six months and help pe…

This study is testing if adding a drug called bevacizumab to a standard lung cancer drug (osimertinib) works better to control cancer that has spread to the brain. It is for adults with a specific type of advanced lung cancer (EGFR-positive non-small cell lung cancer) who have no…

This study is testing combinations of three drugs—brentuximab vedotin, nivolumab, and ipilimumab—to see if they work better together to control Hodgkin lymphoma that has come back or hasn't responded to previous treatments. It involves 146 patients aged 12 and older and aims to f…

This large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…

This study is testing if a two-drug oral combination works better than a single oral drug to control symptoms and reduce cancer cells in patients with certain aggressive blood cancers, including chronic myelomonocytic leukemia (CMML). It is a Phase 2 trial with 132 participants, …

This early-stage study is testing whether adding an experimental drug called berzosertib to standard chemotherapy (cisplatin) and radiation can better treat advanced head and neck cancer. The main goals are to find the safest and most effective dose of this new combination and to…

This large, late-stage trial is testing if adding a new drug called ganitumab to standard chemotherapy helps patients with newly diagnosed Ewing sarcoma that has spread. Ganitumab is designed to block a pathway that helps tumor cells grow. The study aims to see if this combinatio…

This study tested whether adding a new drug called veliparib to an existing chemotherapy (temozolomide) works better for people with small cell lung cancer that has come back or stopped responding to prior treatment. The goal was to see if the combination could help control the c…

This large study is testing if adding an immunotherapy drug called nivolumab to standard kidney cancer surgery helps prevent the cancer from coming back. About 819 patients with kidney cancer that hasn't spread far will have surgery, with half also receiving the drug before and a…

This large, late-stage trial aims to find out which of two three-drug combinations works better to control newly diagnosed multiple myeloma in patients who cannot undergo intensive stem cell transplant. It directly compares a standard chemotherapy pair (melphalan and prednisone) …

This study is testing if adding a short, precise course of radiation (SBRT) to an immunotherapy drug (pembrolizumab) works better than the drug alone for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. It aims to see if the combination helps control…

This early-stage study is testing the safety and best dose of two drugs, riluzole and sorafenib, when given together. It's for people with advanced solid tumors or melanoma that have spread and are no longer responding to standard treatments. The goal is to see if this combinatio…

This study is testing if adding a new drug called pevonedistat to two standard chemotherapy drugs (carboplatin and paclitaxel) works better for people with advanced non-small cell lung cancer. It is for adults whose cancer has gotten worse after treatment with immunotherapy. The …

This study is testing an oral drug called cabozantinib to see if it can control the growth of two aggressive bone cancers, osteosarcoma and Ewing sarcoma, in young patients whose cancer has returned or spread after standard treatment. The drug works by blocking signals tumors nee…

This study is testing a new combination of three immune-based treatments for adults with advanced stomach or head and neck cancer that has returned or spread after standard therapy. The treatment involves giving patients specially engineered immune cells (CAR-NK cells) along with…

This early-stage study is testing a new combination of two drugs, duvelisib and nivolumab, for patients with advanced stages of two rare skin lymphomas: mycosis fungoides and Sézary syndrome. The main goal is to find the safest and most effective dose of the drug combination. Res…

This study is testing two different drug combinations for adults with angiosarcoma, a rare and aggressive cancer. For patients who haven't had a specific type of chemo, it compares standard chemo (paclitaxel) alone to that chemo plus an immunotherapy drug (nivolumab). For patient…

This early-stage trial is testing the safety and early effectiveness of a drug called pembrolizumab in children with aggressive brain tumors that have come back or stopped responding to standard treatments. The drug is an immunotherapy, which aims to help the body's own immune sy…

This early-phase study is testing a combination of immunotherapy drugs (nivolumab and ipilimumab) along with standard transplant medications (tacrolimus and prednisone) in kidney transplant patients with advanced skin cancers that have spread or cannot be removed by surgery. The …

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This study tests whether two immunotherapy drugs (ipilimumab and nivolumab) can help control recurrent, aggressive brain tumors that have many genetic mutations. The treatment aims to help the body's immune system recognize and attack the cancer cells. Researchers are measuring w…

This study is testing an oral drug called sapanisertib for people with advanced bladder cancer that has a specific genetic mutation (TSC1 or TSC2) and has stopped responding to standard platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and control the …

This study is testing whether adding radiation therapy to two immunotherapy drugs helps control advanced lung and colorectal cancer better than the drugs alone. It enrolled 110 patients whose cancer had spread and had stopped responding to prior treatments. The main goals are to …

This early-stage study is testing a combination of two oral drugs, cediranib and selumetinib, in patients with advanced solid tumors that cannot be removed by surgery and have no standard treatment options. The main goals are to find the safest dose and understand the side effect…

This early-stage study is testing a new oral drug called ropidoxuridine (IPdR) in patients with advanced gastrointestinal cancers that have spread. The main goal is to find the safest dose of the drug when taken daily alongside standard radiation therapy. Researchers hope the dru…

This study aimed to test if a personalized immune cell therapy could prevent or delay the return of advanced gastrointestinal cancers (like pancreatic, liver, or colon cancer) after standard treatment like surgery. It was for patients whose cancer had specific genetic mutations a…

This study is testing whether a drug called pembrolizumab can help prevent Merkel cell carcinoma from returning after surgery. It compares the drug against standard monitoring in 280 patients whose cancer was completely removed. The goal is to see if this immunotherapy helps the …

This early-stage study is testing the safety and best dose of two drugs, ibrutinib and lenalidomide, when given together. It is for adults whose B-cell non-Hodgkin lymphoma has come back or has not responded to previous treatments. The goal is to see if combining these drugs is s…

This study is testing whether taking two oral drugs together—palbociclib and binimetinib—is better than taking one of them alone for controlling advanced cancers that have specific genetic changes called RAS mutations. It focuses on certain hard-to-treat cancers like low-grade ov…

This study tests whether the immunotherapy drug pembrolizumab helps patients with desmoplastic melanoma, a rare type of skin cancer. It includes two groups: patients who can have surgery (to see if the drug shrinks tumors beforehand) and patients whose cancer cannot be surgically…

This study is testing a drug called trametinib in children whose juvenile myelomonocytic leukemia (JMML) has come back or hasn't responded to other treatments. The goal is to see if the drug can control the cancer by blocking signals that help the cancer cells grow. Researchers w…

This study is testing a combination of two drugs, olaparib and radium-223, for men with advanced prostate cancer that has spread to the bones and is no longer responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can slow the cance…

This study is testing whether a new drug called pevonedistat can help control advanced bile duct cancer that starts in the liver. It is being tested alone and in combination with two standard chemotherapy drugs (carboplatin and paclitaxel) in about 40 patients whose cancer has wo…

This early-stage trial is testing a combination of two oral drugs, osimertinib and telaglenastat, for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to standard targeted therapy. The main goals are to …

This large Phase 3 trial aims to find the better treatment combination for patients with advanced, high-risk neuroendocrine tumors (like carcinoid tumors) that have spread. Researchers are comparing a standard drug (octreotide) paired with either interferon or bevacizumab to see …

This study compares two drugs (imatinib and dasatinib) for adults newly diagnosed with a type of blood cancer called chronic myeloid leukemia. Researchers tested standard and higher doses to see which treatment best reduces cancer markers in the blood. The goal is to find the mos…

This study is testing whether a pill called cabozantinib can help control rare cancers that have come back or stopped responding to other treatments in children and young adults. It includes patients with sarcomas, Wilms tumor, and other rare tumors. The drug aims to slow or stop…

This study is for adults with advanced melanoma that cannot be removed by surgery. It compares two immunotherapy combinations to see which helps patients live longer and has fewer severe side effects. One group gets two standard immunotherapy drugs, while the other gets those sam…

This study is testing whether taking two oral drugs, cediranib and olaparib, together can help control advanced cancers that have spread or cannot be surgically removed. It is for adults with specific types of advanced lung, breast, or pancreatic cancer who have already tried at …

This early-stage study is testing whether adding an experimental drug called berzosertib (M6620) to standard chemotherapy (carboplatin and gemcitabine) is safe and might work better for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned. The main goal …

This study is testing whether a new drug called PEN-866, when combined with two standard chemotherapy drugs (vincristine and temozolomide), can help control aggressive cancers that have returned or not responded to other treatments. It is for adolescents and young adults (ages 12…

This study is testing two different treatment plans for adults aged 65 and older with a type of blood cancer called acute lymphoblastic leukemia (ALL). One plan combines an immunotherapy drug (blinatumomab) with standard chemotherapy. The other plan combines a targeted drug (dasa…

This study is for patients with newly diagnosed, high-risk soft tissue sarcomas that can be removed by surgery. It tests whether adding a drug called pazopanib to standard pre-surgery treatments (radiation with or without chemotherapy) helps shrink tumors more effectively and imp…

This study is for people with advanced papillary kidney cancer that has spread. It compares the standard drug cabozantinib alone against cabozantinib combined with a newer immunotherapy drug called atezolizumab. The goal is to see if the two-drug combination can better control th…

This large, late-stage study is testing whether adding an immunotherapy drug called pembrolizumab to standard chemotherapy works better for treating advanced or recurrent endometrial cancer. It involves over 800 patients with stage III, IV, or returning cancer. The goal is to see…

This trial is testing whether the drug crizotinib can help control advanced cancers that have a specific genetic change called MET amplification. It is for adults with solid tumors, lymphoma, or multiple myeloma that have stopped responding to other treatments. The drug works by …

This large study is testing whether a drug called pembrolizumab can help prevent cancer from returning in people who have had surgery for muscle-invasive bladder or upper urinary tract cancer. After surgery, participants are randomly assigned to either receive the drug (which hel…

This study is testing if a pill called olaparib can help control advanced blood cancers (acute myeloid leukemia or myelodysplastic syndrome) that have come back or haven't responded to standard treatments. It is for adults whose cancer has a specific genetic change called an IDH …

This early-stage study is testing a new two-drug combination for women with ovarian cancer that has returned after previous treatment. The main goal is to find the safest and most effective dose of an experimental pill (peposertib) when given with a standard chemotherapy drug. Re…

This study is testing whether adding two targeted drugs, dabrafenib and trametinib, after standard radiation therapy works better for children and young adults with a specific type of aggressive brain tumor. The treatment is for patients whose tumors have a particular genetic cha…

This study aimed to see if approved immunotherapy drugs (nivolumab with or without ipilimumab) could help people with early-stage colorectal or gastroesophageal cancer delay or avoid major surgery to remove their tumors. The goal was an 'organ preservation' strategy, using the dr…

This early-stage trial is testing whether adding an experimental pill called peposertib to a targeted radiation treatment (lutetium Lu 177 dotatate) is safe and effective for patients with advanced neuroendocrine tumors in the digestive system. The main goal is to find the best d…

This early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs …

This study is testing if adding an immunotherapy drug (atezolizumab) to standard chemotherapy before surgery works better for treating early-stage triple-negative breast cancer. It will compare two groups: one gets chemo alone, and the other gets chemo plus the immunotherapy drug…

This study is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can help control advanced thyroid cancer that has stopped responding to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this three-drug a…

This study is testing whether taking planned breaks from two targeted cancer drugs (dabrafenib and trametinib) is as effective as taking them continuously for people with advanced melanoma that has a specific genetic change (BRAF mutation). It aims to see if the 'on-and-off' sche…

This study is testing whether a drug called afatinib can help people with advanced cancers that have a specific genetic change called a HER2 mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers are enrolling about 40 patients whose cancers have…

This study is testing whether adding the drug lenalidomide to a standard chemotherapy combination works better for treating newly diagnosed aggressive lymphoma. About 350 patients with stage II-IV disease will receive either the standard treatment or the standard treatment plus l…

This study is testing a two-part treatment for patients with advanced skin cancers or rare lymphomas that have not responded to other therapies. First, a modified virus is injected directly into tumors to help the immune system recognize cancer. Then, an immunotherapy drug is giv…

This study is for men whose prostate cancer is starting to come back, shown by a rising PSA level, after their initial surgery or radiation. It compares two treatment plans: one uses a standard hormone-blocking drug (bicalutamide) alone, and the other combines that drug with an e…

This study is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination helps more patients achieve a deep remission with no detectable cancer ce…

This large, late-stage trial is testing which combination of chemotherapy drugs works best for women with a specific type of ovarian or fallopian tube cancer (mucinous adenocarcinoma). It compares two standard drug pairs, with or without an added drug (bevacizumab) that blocks tu…

This study is testing whether the drug selumetinib can shrink or slow the growth of large, inoperable nerve tumors (plexiform neurofibromas) in adults with Neurofibromatosis Type 1 (NF1). Participants take capsules twice daily for as long as they tolerate the drug and their disea…

This study is testing whether a combination of two drugs, belinostat and either guadecitabine or ASTX727, can help control advanced chondrosarcoma, a rare type of bone cancer that cannot be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors o…

This study is testing a new treatment approach for people with locally advanced rectal cancer that has a specific genetic marker (MSI-H/dMMR). The goal is to see if giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short, intense course of radiation before su…

This study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…

This study is testing whether the drug pomalidomide can help control Kaposi sarcoma, a type of skin cancer often linked to HIV. It involves 45 adults with measurable skin lesions, who will take the drug in repeating cycles for up to two years. The main goal is to see if the treat…

This large study tested whether adding a targeted drug (bevacizumab) to standard chemotherapy helps prevent cancer from returning in patients with high-risk stage II colon cancer who have had surgery. Over 2,400 patients were randomly assigned to receive either standard chemother…

This study is testing whether adding a targeted drug called ipatasertib to a standard chemotherapy (paclitaxel) can help control advanced solid tumors that have specific genetic changes and have stopped responding to similar chemotherapy drugs. It aims to see if this combination …

This study is testing whether adding immune-boosting drugs (nivolumab and ipilimumab) to standard chemotherapy can help people with newly diagnosed glioblastoma, a very aggressive brain cancer. Researchers will track 47 adults who have already had surgery and initial treatment, l…

This study is testing a new three-part treatment for people with advanced cancers that have spread. It combines a new pill (peposertib), an immunotherapy drug (avelumab), and a short, high-dose course of radiation. The goal is to see if this combination can better control cancer …

This study is for people whose pancreatic cancer has spread and worsened after their first treatment. It compares a standard chemotherapy (FOLFIRI) against the same chemo plus an experimental drug called veliparib. The goal is to see if the combination helps patients live longer …

This study is testing whether adding a new immunotherapy drug (varlilumab) to an existing one (nivolumab) works better than nivolumab alone for patients with aggressive B-cell lymphomas that have come back or stopped responding to standard treatments. The goal is to see if the tw…

This study is testing whether combining two cancer drugs works better than using just one to treat an aggressive form of kidney cancer that has spread or cannot be removed by surgery. The trial is enrolling patients of all ages, from children to adults. Researchers want to see if…

This study is testing if a new drug combination works better than a standard drug alone to shrink melanoma tumors before surgery. It involves 60 adults with stage III melanoma that can be surgically removed. The goal is to see if the combination helps the immune system attack the…

This study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…

This study is testing if adding an experimental drug called berzosertib (M6620) to standard chemotherapy (topotecan) works better than chemotherapy alone for adults whose small cell lung cancer has come back. The goal is to see if the combination can help control the cancer for l…

This early-stage study is testing a method to personalize the dose of a cancer drug called pazopanib for patients with advanced solid tumors. Researchers will check drug levels in patients' blood and adjust the dose to try to improve safety and effectiveness. The main goal is to …

This study is for people with advanced bladder cancer that has spread and is no longer responding to standard immunotherapies. It compares a new two-drug chemotherapy combination (eribulin plus gemcitabine) against the doctor's usual choice of chemotherapy. The main goal is to se…

This large, late-stage trial aims to find the best way to combine immunotherapy and chemotherapy for patients with advanced non-squamous lung cancer. It will compare starting with immunotherapy alone versus starting with both treatments together, and test different approaches if …

This study is testing whether combining two drugs, nilotinib and paclitaxel, can help control advanced solid cancers that have continued to grow or spread despite previous treatment with a similar class of drugs called taxanes. It is for adults whose disease is getting worse. The…

This study is testing whether two drugs, dabrafenib and trametinib, can shrink or stop the growth of advanced cancers that have a specific genetic change called a BRAF V600 mutation. It is for patients with solid tumors, lymphoma, or multiple myeloma that have not responded to ot…

This study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy (carboplatin) works better than a different standard combination (docetaxel + carboplatin) for men with advanced prostate cancer that has spread and is no longer responding to …

This early-stage study is testing the safety and best dose of a three-drug combination (entinostat, nivolumab, and ipilimumab) for people with advanced solid tumors that have spread and are hard to treat. The goal is to see if boosting the immune system with two drugs while using…

This early-stage study is testing a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in patients with advanced pancreatic cancer that has spread or cannot be surgically removed. The main goals are to find the safest and most effective dose and to understand the …

This large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…

This study is testing a combination of two immunotherapy drugs, tiragolumab and atezolizumab, for children and adults with rare, aggressive cancers that have come back or stopped responding to standard treatments. These cancers are missing specific genes (SMARCB1 or SMARCA4). The…

This study is for people with advanced pancreatic cancer that has spread and who have specific inherited BRCA gene mutations. It compares a standard maintenance drug (olaparib) alone against the same drug combined with an immunotherapy drug (pembrolizumab). The goal is to see if …

This early-stage study is testing the safety and best dose of a new three-drug combination for small cell lung cancer that has returned after initial treatment. The combination includes a pill (tazemetostat), a chemotherapy (topotecan), and an immunotherapy (pembrolizumab), aimin…

This study is testing a new personalized vaccine treatment for people who have had surgery for non-small cell lung cancer. The goal is to see if the vaccine, given with an immune-boosting drug, can train the body's immune system to recognize and attack any remaining cancer cells …

This study is testing if a very low dose of the drug apalutamide can help control prostate cancer before surgery. It involves men whose cancer is still confined to the prostate gland. The main goal is to see if this short, low-dose treatment can effectively lower PSA levels, a ke…

This trial is testing whether the drug osimertinib can help control advanced cancers that have specific changes (mutations) in a gene called EGFR. The drug works by blocking the faulty protein these mutations create, which may slow or stop cancer growth. The study is for adults w…

This study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…

This study is testing whether a combination of two hormone-blocking drugs can control a rare and difficult-to-treat cancer of the salivary glands. It is for adults whose cancer has returned after treatment or has spread, and whose tumors test positive for a specific hormone recep…

This study is testing if adding a pill called venetoclax to standard chemotherapy works better than chemotherapy alone for people with aggressive types of B-cell lymphoma. The goal is to better control the cancer and keep it from coming back. About 363 adults with specific, hard-…

This study is testing whether a combination of three drugs can help control advanced, aggressive neuroendocrine cancers that have worsened after one prior treatment. The drugs work together: one aims to block tumor growth directly, while the other two aim to help the patient's ow…

This study aimed to test if an oral drug called APG-115 could stop or slow the growth of early-stage mesothelioma in people with a specific inherited gene mutation (BAP1). Participants would have taken the drug at home in repeating cycles while undergoing regular scans and biopsi…

This large study compared two treatment approaches for newly diagnosed multiple myeloma, a blood cancer. Researchers tested whether a lower dose of one drug (dexamethasone) combined with lenalidomide works as well as the standard higher dose, with fewer side effects. Patients who…

This study is testing if adding an experimental drug called AZD1775 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone. It is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based…

This study is testing whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with aggressive small cell lung cancer or high-grade neuroendocrine cancers that have returned after prior treatment. The first part of the trial aims to find the safest …

This large, late-stage trial is testing if adding a pill called cabozantinib to an immunotherapy drug (avelumab) is better than the immunotherapy alone for keeping advanced bladder cancer from growing or returning. It is for patients whose cancer did not worsen after their first …

This early-stage study is testing a new oral drug called navtemadlin (KRT-232) in combination with standard chemotherapy for adults newly diagnosed with a fast-growing blood cancer called acute myeloid leukemia (AML). The main goals are to find the safest and most effective dose …

This study is testing whether adding an immunotherapy drug called dinutuximab to standard chemotherapy works better for children newly diagnosed with high-risk neuroblastoma, a serious childhood cancer. The trial involves 42 young patients and aims to see if this combination is s…

This study is testing a combination of three hormone-blocking drugs given to men before prostate removal surgery. The goal is to see if this approach better controls the cancer. Researchers are also using advanced PET and MRI scans to see if they can more accurately detect and mo…

This study is testing whether adding an immunotherapy drug called pembrolizumab to standard radiation treatment is better at preventing cancer from returning in patients with early-stage endometrial cancer. The trial will compare radiation alone versus radiation plus pembrolizuma…

This study is testing whether a two-part immunotherapy can help patients with advanced melanoma whose cancer has continued to grow despite standard immune-based treatments. It combines a modified virus injected directly into tumors (T-VEC) with an intravenous drug (pembrolizumab)…

This trial is testing an oral drug called ulixertinib in patients with advanced cancers that have specific, less common changes in a gene called BRAF. The drug aims to block signals that tell cancer cells to grow, potentially slowing or stopping the disease. It is for patients wi…

This study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…

This study is testing whether a drug called atezolizumab can help control advanced forms of two rare cancers: chondrosarcoma (bone cancer) and clear cell sarcoma (soft tissue cancer). The drug works by helping the patient's own immune system recognize and attack the cancer cells.…

This study is testing whether the immunotherapy drug nivolumab can help control advanced cervical cancer that has returned or spread after initial treatment. It involves 26 women with persistent or recurrent cervical cancer who have already tried one prior chemotherapy regimen. T…

This study aimed to see if a targeted pill (erdafitinib) alone or combined with an immunotherapy drug (atezolizumab) could shrink aggressive bladder tumors before surgery. It was for patients whose cancer had grown into the muscle wall of the bladder and who could not receive the…

This study is testing whether a combination of pills (ASTX727 and venetoclax) is as safe and effective as standard intravenous chemotherapy for younger adults with a high-risk type of acute myeloid leukemia (AML). The goal is to control the cancer and improve survival. The trial …

This study is testing an oral drug called rogaratinib for adults with advanced sarcoma or a rare stomach tumor called SDH-deficient GIST. The drug aims to block specific proteins that help these cancer cells grow, with the goal of shrinking tumors and controlling the disease. It …

This early-stage trial is testing the safety and best dose of a two-drug combination (vorinostat and azacitidine) for patients with advanced nasal and throat cancers that have returned or spread. The study aims to see if these drugs, which work differently to stop cancer cell gro…

This study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy drug (irinotecan) works better than the chemotherapy alone. It is for people with advanced stomach or esophageal junction cancer that has a specific genetic change (TP53 mutati…

This early-stage trial is testing a new drug called telaglenastat, given alongside standard radiation and chemotherapy (temozolomide), for people with certain types of brain tumors (IDH-mutant astrocytomas). The main goals are to find the safest dose of the new drug combination a…

This early-stage study is testing a new four-drug combination for a very aggressive type of lymphoma that has returned or stopped responding to standard treatments. The goal is to see if combining an immunotherapy drug (atezolizumab) with two chemotherapy drugs and a targeted ant…

This study is testing whether a drug called pazopanib can slow or stop the growth of carcinoid tumors that are getting worse. It compares pazopanib against a placebo (inactive pill) in 171 patients whose tumors have progressed. The main goal is to see if the drug helps patients l…

This early-stage study is testing a new combination of three drugs for adults with an aggressive type of lymphoma that has come back or not responded to previous treatments. The main goal is to find the safest and most effective dose of these drugs when used together. Researchers…

This study is testing a new oral drug called Elimusertib in children and young adults whose solid tumors have come back or stopped responding to standard treatments. The main goals are to find the safest dose and see if the drug can shrink tumors, particularly in certain types of…

This study is for people with advanced colorectal cancer that has spread or cannot be removed by surgery and has a specific BRAF gene mutation. It tests if adding the immunotherapy drug nivolumab to two standard targeted drugs works better to control the cancer and stop it from g…

This study is testing if the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called an ALK rearrangement. It is for people with various solid tumors or blood cancers (excluding certain lung cancers and lymphomas) that have not…

This study is testing whether an oral drug called INQOVI can stop or improve very early-stage mesothelioma in people born with a specific gene mutation (BAP1) that makes them highly likely to develop this cancer. Participants take the pill for six months while doctors closely mon…

This study tested whether the immunotherapy drug atezolizumab, alone or with bevacizumab, could help control advanced alveolar soft part sarcoma, a rare cancer. It involved 63 patients with cancer that had spread and could not be removed by surgery. The main goal was to see if th…

This large, late-stage trial is comparing two treatment approaches for patients with a bone marrow disorder (MDS) and severe anemia. It tests whether a drug called lenalidomide works better alone or when combined with a hormone (epoetin alfa) that helps the body make red blood ce…

This early-stage study is testing a combination of three drugs—lenalidomide, dinutuximab, and isotretinoin—in children and young adults whose neuroblastoma has returned or hasn't responded to standard treatments. The main goal is to find the safest dose of lenalidomide when given…

This early-phase study is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The main goals are to find t…

This study tested whether combining two targeted drugs works better than either drug alone to control advanced non-small cell lung cancer that has worsened after initial chemotherapy. It involved 125 patients whose tumors lack a specific genetic marker (EGFR mutation). The goal w…

This study is testing whether combining two or three different cancer drugs works better than single drugs to control advanced cancers that have come back or spread. It is for adults with advanced ovarian, breast, lung, prostate, or colorectal cancer who have few other treatment …

This large study aimed to find the best treatment for women with a common type of early-stage breast cancer. It used a special gene test (Oncotype DX) to see if hormone therapy alone was just as good as hormone therapy plus chemotherapy for women with a mid-range test score. The …

This study is for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. It compares a new two-drug combination (bevacizumab + anetumab ravtansine) against a standard two-drug combination (bevacizumab + paclit…

This study is testing how well the drug palbociclib works for patients with advanced cancers that have not responded to other treatments and have specific changes in their CDK4 or CDK6 genes. The drug aims to block signals that tell cancer cells to grow, potentially slowing or st…

This early-stage study is testing a new three-drug combination for adults newly diagnosed with a serious blood cancer called acute myeloid leukemia (AML). The goal is to find a safe and effective dose. One drug is a targeted radioactive therapy designed to seek out and destroy ca…

This study is for people with advanced kidney cancer that has spread to their bones. It tests if adding a radioactive drug (radium-223) to a standard cancer pill (cabozantinib) works better than the pill alone. The main goal is to see if the combination can delay bone-related pro…

This study is testing whether adding a targeted drug called olaparib to standard radiation therapy works better than radiation alone for inflammatory breast cancer. It involves 300 patients who have already had surgery and chemotherapy. The goal is to see if this combination help…

This study is testing whether adding a drug called decitabine before standard chemotherapy helps treat acute myeloid leukemia (AML) more effectively. The goal is to see if decitabine can 'prime' or sensitize the cancer cells, making them easier for the chemotherapy drugs to kill.…

This early-stage study is testing a new vaccine therapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to find a safe dose and see if injecting the vaccine directly into the tumor, along with an immune-boosting drug, can help the body's …

This early-stage study is testing an oral drug called alvelestat for people who develop a serious lung scarring condition (BOS) after a stem cell transplant. The goal is to find a safe dose that blocks a harmful enzyme thought to cause the lung damage and to see if that dose can …

This large, late-stage trial is testing whether adding an immunotherapy drug (nivolumab) to standard chemotherapy works better than chemotherapy alone for anal cancer that has spread. It will enroll about 205 adults whose cancer cannot be cured by surgery or radiation. The main g…

This early-phase study is testing the safety and best doses of combining the cancer drug copanlisib with immunotherapy drugs (nivolumab alone or with ipilimumab). It involves 64 adults with advanced solid tumors or lymphoma that have progressed after standard treatments. The goal…

This study is for people with advanced head and neck cancer that has returned or spread after their first immunotherapy treatment stopped working. It compares three different drug combinations to see which one is better at controlling the cancer and helping patients live longer. …

This study is for people aged 75 and older who have just been diagnosed with certain aggressive types of lymphoma. It compares the current standard treatment (a combination of drugs called R-miniCHOP) to that same treatment plus a new oral drug called CC-486. The main goals are t…

This study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …

This study is for people with advanced bile duct, gallbladder, or liver bile duct cancer that has worsened after initial treatment. It tests whether adding a targeted pill called binimetinib to standard chemotherapy (FOLFOX) helps patients live longer and better control the cance…

This study is testing a drug called binimetinib in patients with advanced cancers that have a specific genetic change called an NRAS mutation. The drug works by blocking proteins that cancer cells with this mutation need to grow. Researchers want to see if the drug can shrink the…

This trial is testing whether a pill called ipatasertib can help control advanced cancers that have stopped responding to other treatments and have a specific genetic change called an AKT mutation. About 35 patients with various advanced cancers, including solid tumors, lymphoma,…

This study is testing the safety and effectiveness of combining two oral drugs, trametinib and navitoclax, for patients with advanced solid tumors that have spread and have specific KRAS or NRAS genetic mutations. The goal is to find the best dose and see if the combination can s…

This study tested a combination of two drugs, cediranib and olaparib, for people with recurrent ovarian, fallopian tube, peritoneal, or triple-negative breast cancer. The goal was to see if using both drugs together is safe and works better than using olaparib alone to control th…

This study is testing whether a combination of two immunotherapy drugs, atezolizumab and tiragolumab, can help control advanced rare solid tumors. It involves 12 adult patients whose cancer has progressed despite standard treatment. Researchers will take tumor and blood samples b…

This study is testing whether the drug AZD1775 can shrink or stop the growth of advanced cancers that have specific genetic changes called BRCA1 or BRCA2 mutations. The drug works by blocking a protein called WEE1 that these cancer cells may need to survive. The trial will involv…

This study is testing an experimental pill called GSK2636771 for people with advanced cancers that have stopped responding to other treatments. The drug is specifically for cancers that have completely lost a protein called PTEN. Researchers want to see if the pill can shrink the…

This study is testing if adding a new drug called M6620 to a standard chemotherapy (gemcitabine) works better than the chemotherapy alone for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum drugs. The main goal is…

This trial is testing how well the drug larotrectinib works for people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug is designed to block the abnormal protein made by this gene change, which may slow or stop cancer growth. The study is …

This early-stage study is testing the safety and best dose of a new targeted drug, anetumab ravtansine, when combined with other cancer treatments. It is for people with advanced pancreatic cancer that has a specific marker called mesothelin. The goal is to see if these combinati…

This study is comparing two different drug combinations for people with an advanced, mixed-type liver cancer that cannot be removed by surgery. One group gets standard chemotherapy plus an immunotherapy drug. The other group gets those same drugs plus an additional medication des…

This early-stage study is testing a combination of three drugs—bortezomib, sorafenib, and decitabine—to treat acute myeloid leukemia (AML). The main goal is to find the safest and most effective dose. The study is for adults with AML who are older, have a type that is hard to tre…

This study is testing whether the immunotherapy drug nivolumab can help keep acute myeloid leukemia (AML) from coming back after successful chemotherapy. It will compare giving nivolumab as a long-term maintenance treatment against standard observation in 82 adults who are in rem…

This study is testing whether adding an experimental drug called veliparib to standard chemotherapy (temozolomide) helps patients with newly diagnosed glioblastoma, a fast-growing brain cancer, live longer. About 447 patients whose tumors have a specific genetic feature (MGMT pro…

This study is testing whether combining two or three newer drugs works better than standard chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based drugs. It will involve about 120 women who have alr…

This large, late-stage study aims to find the most effective and tolerable first treatment for chronic lymphocytic leukemia (CLL) in people aged 65 and older. It randomly assigns 547 participants to one of three drug regimens: a standard chemotherapy combo, a newer targeted drug …

This early-stage trial is testing a combination of three drugs—copanlisib, olaparib, and durvalumab—in patients with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find the safest and most effective dose of this combination for people …

This large study aimed to find out if adding chemotherapy to standard hormone therapy helps women with a specific type of early-stage breast cancer that has spread to 1-3 lymph nodes. Over 5,000 participants were randomly assigned to receive either hormone therapy alone or hormon…

This study is testing a drug called trastuzumab deruxtecan (DS-8201a) for young people (ages 12-39) whose HER2-positive osteosarcoma, a type of bone cancer, has come back. The drug is designed to act like a targeted missile, attaching to cancer cells and delivering chemotherapy d…

This study is testing a new type of imaging scan to see if it can better locate prostate cancer in the body. It is for men who have been newly diagnosed with high-risk cancer or whose cancer has returned after initial treatment. Participants receive an injection of a radioactive …

This study is testing a special type of imaging scan (called FLT PET/CT) to see if it can accurately measure how well a patient's acute myeloid leukemia (AML) is responding to initial chemotherapy. The goal is to see if this scan, which tracks rapidly dividing cells, can provide …

This study is testing a new type of PET scan to see if it can better predict whether prostate cancer will come back after surgery. Men with high-risk prostate cancer planning to have their prostate removed will get this new scan before their operation. Researchers will then follo…

This study is testing if a new type of imaging scan can better detect prostate cancer that has spread to other parts of the body, like bones. Men with metastatic prostate cancer will get two different scans to compare their accuracy. The goal is to see if the new scan, which uses…

This study is testing a special imaging scan to see if it can predict whether hormone therapy will work for patients with advanced breast cancer that has spread. The scan uses a radioactive form of estrogen to 'light up' cancer spots in the body. If successful, this scan could he…

This study is testing whether a vaginal sample you collect yourself at home is as good at finding the HPV virus as a sample a doctor collects during a pelvic exam. It involves 520 women who are already scheduled for a follow-up cervical exam. The goal is to make cervical cancer s…

This study is testing whether people can collect their own vaginal samples for HPV testing as accurately as a doctor can collect cervical samples during a pelvic exam. The goal is to make cervical cancer screening more accessible and comfortable, especially for those who avoid cl…

This study is testing whether curcumin, the active compound in turmeric, can help prevent stomach cancer in people who have a pre-cancerous stomach condition. Fifty participants with chronic atrophic gastritis or gastric intestinal metaplasia will take either curcumin or a placeb…

This study is testing whether taking aspirin on different schedules can help prevent colorectal cancer in people who have precancerous growths called adenomas. Researchers are comparing daily aspirin, intermittent aspirin, and placebo in 81 participants over 12 weeks. The goal is…

This study is testing an experimental vaccine designed to teach the body's immune system to attack and kill colon polyp cells. It aims to prevent these polyps, which can turn into colorectal cancer, from growing back after removal. About 110 people who recently had a large or hig…

This study is testing whether the HPV vaccine, which helps prevent certain cancers, can still help build a strong immune response in people who are about to receive a kidney transplant. Kidney transplant patients must take powerful drugs to prevent organ rejection, but these drug…

This study is testing whether metformin, a common diabetes medication, can help prevent oral cancer in people who have precancerous red or white patches in their mouth. Twenty-six participants with these high-risk lesions will take metformin pills daily for about 3 months. Resear…

This trial is testing a vaccine called Nous-209 in people with Lynch syndrome, a genetic condition that greatly increases the risk of colorectal and other cancers. The vaccine is designed to teach the body's immune system to recognize and attack early cancer cells. Researchers wa…

This study tests whether treating people with high-risk smoldering multiple myeloma—a pre-cancer condition—with a three-drug combination can prevent or delay progression to active cancer. Fourteen participants receive injections and infusions of daratumumab, carfilzomib, and dexa…

This study is testing if just one dose of the HPV vaccine can effectively prevent cervical cancer in young women. It involves 5,000 women in Costa Rica aged 18-30 who have not been vaccinated before. Participants receive either one dose of an HPV vaccine or a control vaccine, and…

This study is testing whether a combination of a three-part vaccine and an immune system booster can prevent colon and other cancers in people with Lynch syndrome, a genetic condition that greatly increases cancer risk. The vaccine aims to train the body's immune system to recogn…

This study is testing whether people can collect their own vaginal samples at home for HPV testing as accurately as a doctor collects samples in a clinic. It involves 500 people who have already been referred for a follow-up cervical exam. The goal is to make cervical cancer scre…

This study is testing whether a daily aspirin pill can help prevent Barrett's esophagus from returning after it has been successfully treated with a procedure called radiofrequency ablation. It involves 21 people who have had their Barrett's esophagus cleared. Participants are ra…

This study is testing whether a single dose of the HPV vaccine is just as effective as the standard two doses at preventing infections that cause cervical cancer. It involves over 27,000 girls aged 12-16 in Costa Rica, comparing two different HPV vaccines. The goal is to make vac…

This study is testing whether a daily broccoli seed and sprout extract can boost the body's natural ability to clear out cancer-causing chemicals that firefighters breathe in during their work. It involves 66 active, non-smoking firefighters who will take either the broccoli extr…

This study is testing if a widely used cholesterol-lowering drug called simvastatin can help prevent liver cancer in people who already have liver cirrhosis (scarring). It involves 52 participants who will take either the drug or a placebo (sugar pill) daily for 6 months. Researc…

This small, remote pilot study is testing whether a type of counseling called Acceptance and Commitment Therapy (ACT) can help adults with sickle cell disease who have trouble sleeping. Participants will have weekly video coaching sessions for 8 weeks and wear a wrist device to t…

This study provides standard cancer care and collects health information from patients at the National Cancer Institute who are not enrolled in other research trials. It aims to create a large database of patient experiences to help generate ideas for future cancer research. Part…

This study aims to understand how a specific type of brain tumor (glioma) changes and becomes more aggressive over time. Researchers will use special brain scans to track chemical levels in the tumors of about 42 adults who have this condition. The goal is to learn if these chemi…

This study is following thousands of women in Costa Rica for 10 years to see how well the HPV vaccine protects against cervical cancer over the long term. Researchers are comparing women who received the vaccine years ago with a new group of unvaccinated women. The goal is to und…

This study collects tumor tissue and blood samples from people with cancer to help researchers find new targets for future treatments. Participants are adults who are already having surgery or biopsy for their cancer care. No experimental treatments are given—researchers only col…

This study is looking at whether a genetic test called the Genomic Prostate Score (GPS) can work together with MRI scans to help doctors better select patients for a less-invasive prostate cancer treatment called focal therapy. Researchers will analyze past data and tissue sample…

This study aims to understand why some cancer patients experience severe or unexpected side effects from their medications. Researchers will collect blood samples from up to 100 patients already enrolled in other NIH cancer trials who are having bad reactions. By measuring drug l…

This study collects white blood cells from people with certain leukemias or lymphomas that have not been cured by standard treatments. The cells are collected through a 4-6 hour blood filtering process called leukapheresis and then frozen. The goal is to have these cells ready an…

This study collects blood or bone marrow samples from people with blood cancers like leukemia and lymphoma. Researchers will study these samples in the lab to better understand how these cancers work and to find new targets for future treatments. The study does not test a new the…

This study aims to see if researchers can measure how much of an oral cancer drug (abemaciclib) gets into a person's aggressive brain tumor and the fluid surrounding it. Participants are adults aged 18-39 with a recurrent high-grade glioma. They take the drug for a few days befor…

This study aims to create a collection, or biobank, of biological samples from people with breast, ovarian, or uterine cancers, as well as from some of their relatives. Researchers will collect samples like blood, urine, and leftover tumor tissue to store for future research proj…

This study analyzes tumor samples from cancer patients who responded exceptionally well to treatments that typically don't work for most people with their disease. Researchers examine the genetic makeup of these tumors to understand what makes some patients respond so dramaticall…

This study aims to understand why some liver cancer patients respond to immunotherapy while others do not. Researchers are collecting blood, tissue, and health data from 132 adults with liver cancer who have received or will receive immunotherapy. By analyzing these samples over …

This study observes cancer patients who get COVID-19 to understand how the virus affects their cancer treatment and recovery. Researchers collect blood samples and medical information from 1,877 participants over two years to learn about immune responses and treatment changes. Th…

This study aims to understand the long-term safety of gene therapy treatments given to children with cancer. Researchers will follow up to 500 participants for 15 years to monitor for any delayed side effects that might appear months or years after treatment. The study involves r…

This study aims to understand how radiation therapy for cancer affects the body by collecting blood and urine samples from patients. Researchers will analyze these samples to see changes in genes, cells, and hormones. The goal is to gather knowledge, not to provide a new treatmen…

This is a long-term observational study designed to understand if exposures common in farming—like pesticides, fuels, and dust—increase the risk of developing cancer and other diseases. It follows nearly 90,000 licensed pesticide applicators and their families in Iowa and North C…

This early-stage study is testing different dose schedules of the drug vorinostat when given with standard chemotherapy drugs (carboplatin or paclitaxel) in patients with advanced solid tumors. The main goal is to understand how the body processes the drugs, check for safety, and…

This study aims to understand how Neurofibromatosis Type 1 (NF1) changes over many years in children and adults. Researchers will follow about 260 participants for up to 10 years, performing regular check-ups, scans, and tests to track tumors, pain, and quality of life. The goal …

This large, long-term study aims to find out if regular screening for prostate, lung, colorectal, and ovarian cancers helps people live longer. It enrolled about 154,900 men and women aged 55 to 74, randomly assigning half to receive screening tests and half to receive their usua…

This study aims to better understand adrenocortical cancer, a rare and aggressive disease, by looking back at the medical records of about 1,000 patients. Researchers will analyze how long patients lived and how they responded to different treatments, hoping to find patterns that…

This study follows people for up to 15 years after they received CAR T-cell gene therapy for blood cancers like lymphoma and leukemia. Researchers check in annually through clinic visits, phone calls, or emails to monitor for any long-term side effects or health issues. The study…

This study aims to learn from the past to make future cancer treatments safer. Researchers are reviewing the medical records of 500 children and adults who received immunotherapies, like CAR T-cell therapy, to understand their side effects. The goal is to identify patterns and ri…

This study aims to understand why some families get cancer more often than others. Researchers are following over 5,000 people from families with unusual patterns of cancer to learn about the roles of genetics and environment. Participants provide health information and samples, …

This study aims to understand why some families have a higher risk of developing blood and lymph node cancers like leukemia and lymphoma. Researchers are observing and collecting health information from families with a history of these cancers to identify genetic and environmenta…

This study aims to understand why certain cancers develop at younger ages in people from different racial and ethnic backgrounds. Researchers will collect tumor tissue and blood samples from 2,400 patients during their regular cancer surgeries. By analyzing these samples, they ho…

This study aims to understand whether exposure to farm environments during childhood increases the risk of developing cancer and other diseases in adulthood. Researchers are following over 64,000 adults who grew up on farms, collecting health information and biological samples ov…

This study aims to understand if changing diet and exercise habits affects gut bacteria in people with melanoma who are receiving immunotherapy treatment. Researchers want to see if a plant-based, high-fiber diet combined with regular exercise increases gut bacteria diversity and…

This study follows women for up to 20 years after they received HPV vaccines to see how long protection lasts. Researchers are comparing women who got one, two, or three doses to understand if fewer doses provide enough long-term immunity. By testing blood samples over time, they…

This study looks back at the medical records of 232 adults with cancer who were treated with an immunotherapy drug called M7824. The goal is to create a complete list of the side effects people experienced, including skin issues. By understanding these risks better, doctors hope …

This study aims to understand why people with HIV and certain cancers (caused by KSHV virus) often lose bone density, which increases fracture risk. Researchers will analyze existing medical records and CT scans from about 40 patients treated at the NIH between 2005 and 2020. The…

This study follows patients for up to 15 years after they received experimental gene therapies for cancers like melanoma and neuroendocrine tumors. The goal is to monitor long-term safety and health outcomes, as required by the FDA. Participants will have regular check-ups, blood…

This large study aims to understand the genetic makeup of lung cancer tumors after they have been surgically removed. It will test tumor samples from 8,300 patients with early-stage non-small cell lung cancer to identify specific genetic changes. The goal is to use this genetic i…

This is an early, small study to understand how the drug DS-8201a works in the body of patients with advanced HER2-positive cancers. Researchers are giving the drug to 62 patients and taking small tumor samples before and after treatment to see how it affects cancer cells and the…

This study aims to understand the genetic causes of chordoma, a rare and often fatal bone cancer. Researchers are asking patients with chordoma who are the only person in their family with the disease to provide a saliva sample and medical history from home. The goal is to find o…

This study is not a treatment, but a long-term safety check. It follows people who previously received gene therapy for cancer in other National Cancer Institute studies. Researchers will contact participants yearly for up to 15 years to check for any delayed side effects or heal…

This study is creating a central collection of samples from healthy volunteers to support laboratory research. It will collect blood, saliva, and other samples from about 1,200 healthy employees at the National Cancer Institute. The samples will be used by scientists for various …

This study collects blood and tumor cells from cancer patients and blood from healthy volunteers. The cells are used in the lab to support research into future immune cell therapies for cancers like melanoma, breast cancer, and lung cancer. No treatment is given in this study; it…

This early study aims to understand how a drug called triapine affects a specific type of aggressive uterine cancer. Researchers will give a single dose of the drug to 12 patients just before their scheduled cancer-removal surgery. They will then compare tumor tissue samples take…